Introduction/Background Endometrial carcinoma is the most common gynecological malignancy in developed countries. Myometrial invasion and lymph node metastasis are important prognostic factors for endometrial cancer. Although lymphadenectomy is part of the full staging procedure, it is known to be associated with increased complication rates and increased comorbidity with prolonged operation time. For this reason, it is important that biomarkers that can predict preoperative myometrial invasion and lymph node metastasis and which can predict poor prognosis can be used. These biomarkers can help in the adjustment of surgical treatment by identifying patients with advanced disease that will benefit from a wide range of surgical procedures but can also help to prevent over-treatment in low-risk patients. In this context, serum L1CAM examination seems promising in endometrial cancer.

Methodology Between January and April 2019, 80 patients with endometrial cancer and 37 control patients were included in the study. Blood samples obtained from the patients were diluted and measured by the spectrophotometric microelisa method with HUMAN L1CAM/CD171. Data were evaluated by IBM SPSS Statistics 20.0 statistical data program and p-value <0.05 was considered statistically significant.

Results It was found that serum L1CAM values were significantly higher in endometrial cancer patients than in the control group (p: 0.000). Although serum L1CAM levels were higher in patients with myometrial invasion and lymph node metastasis, statistically significant results could not be obtained.

Conclusion In this study serum L1CAM measurements were not found to be significantly different in high-risk endometrial cancer patients. We believe that serum L1CAM examination may be effective in the diagnosis of endometrial cancer, but further studies with more patients on low risk and high-risk differentiation should be considered.

Disclosure Nothing to disclose.